Instrument Inactif

Autres langues Impax Laboratories Inc Nasdaq

Actions

US45256B1017

Produits pharmaceutiques

Autres langues

17/07	Amneal Pharmaceuticals Receives Fda Approval for Additional Strengths and Presentations of Iohexol Injection
17/07	Amneal Pharmaceuticals Wins FDA Approval for Additional Generic Iohexol Injection Products
17/07	Amneal Expands Iohexol Injection Portfolio with U.S. FDA Approval of Additional Strengths and Presentations
09/07	Amneal to Report Second Quarter 2026 Results on July 30, 2026
09/07	Amneal to Report Second Quarter 2026 Results on July 30, 2026
08/07	Amneal Pharmaceuticals : and Adalvo Announce FDA Acceptance for Review of Two U.S. ANDAs for Generic Tirzepatide Autoinjector
01/07	Amneal Pharmaceuticals : New U.S. Sterile Manufacturing Facility Selected for FDA PreCheck Pilot Program
01/07	Adalvo and Amneal Pharmaceuticals Receive FDA Acceptance For Review Of Two ANDAs For Generic Tirzepatide Autoinjector
29/06	Eli Lilly, Regeneron Among First Companies in FDA PreCheck Pilot Program
29/06	Lilly, Regeneron selected for US program to review new manufacturing plants faster
29/06	Zambon and Amneal Pharmaceuticals Receive Positive CHMP Opinion for Hopledo for Adults with Parkinson?S Disease and Moderate to Severe Motor Fluctuations
29/06	Amneal Pharmaceuticals, Zambob's Parkinson's Treatment Recommended by European Committee for Approval
29/06	Zambon and Amneal Announce Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations
29/06	Zambon and Amneal Announce Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations
29/06	Amneal Pharmaceuticals, Inc.(NasdaqGS:AMRX) added to Russell 2000 Value-Defensive Index
29/06	Amneal Pharmaceuticals, Inc.(NasdaqGS:AMRX) added to Russell 2000 Growth-Defensive Index
29/06	Amneal Pharmaceuticals, Inc.(NasdaqGS:AMRX) added to Russell 2000 Defensive Index
18/06	FDA Seeks Updated Labeling for Testosterone Therapies
17/06	US progesterone supplies tighten as menopause treatment demand grows
10/06	Dispensary of Hope Launches "Hope Alliance" Campaign with Support from Amneal Pharmaceuticals
08/06	Amneal And Kashiv File IPR Petition On Omalizumab Patent
05/06	Amneal Pharmaceuticals' Reports Crexont Provides Clinical Benefit Over Rytary in Phase 4 Interim Results
05/06	Amneal Pharmaceuticals Announces Interim Phase 4 ELEVATE-PD Results For CREXONT In Parkinson's Disease
05/06	Amneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Reported Benefits of CREXONT® in Parkinson's Disease
04/06	Amneal Pharmaceuticals Announces FDA Approval Of Romidepsin Injection Solution